Floatz logo

Montanide Isa 51

Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
BriaCell Therapeutics Corporation
Phase 3BB
Romidepsin
Celgene
Phase 2BB
Dfn-15
National Cancer Institute (NCI)
Phase 2B
Iscomatrix Adjuvant
National Cancer Institute (NCI)
Phase 1/2CCC
h1299 cell lysates
National Cancer Institute (NCI)
Phase 1/2CCC
Decitabine
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Montanide Isa 51 is also rated in:

Acute Myelogenous Leukemia (AML)Dormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →
melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →